Navigation Links
Gene Can Dampen Chemo Drug Effectiveness
Date:6/10/2009

Alternatives to current breast cancer therapy needed for some patients, study says

WEDNESDAY, June 10 (HealthDay News) -- Women with a certain type of gene may show marked resistance to an important chemotherapy drug used to treat breast cancer, new research suggests.

Scientists at the U.S. National Cancer Institute (NCI) suspect that the variation in the SOD2 gene affects how a patient responds to cyclophosphamide, an agent used against breast tumors, blood cancers and other malignancies. The research is the first to show a mechanism and a biomarker for cyclophosphamide resistance.

Although this is not good news for some patients, the findings have a silver lining: New tests may soon be developed to help doctors screen for genetic markers and create "tailored" therapies, according to an NCI news release.

"In the future, such tests may be used to guide the treatment of patients with the SOD2 variation, ensuring that they receive a therapy that is more effective than cyclophosphamide-based therapy," senior study author Stefan Ambs, of the NCI's Center for Cancer Research, said in the news release.

The study, published online June 9 in Clinical Cancer Research, looked at 588 breast cancer patients in Norway and the United States. Those who had the variation experienced poorer survival on the drug, the researchers found. Scientists believe that the SOD2 variant interferes with the structure and function of an important cellular protein.

More information

The American Cancer Society offers more information on breast cancer.



-- Peter West



SOURCE: U.S. National Cancer Institute, news release, June 9, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Fallout From Failed AIDS Vaccine Could Dampen Research
2. Drinking Dampens Ability to Feel Fear
3. Autoimmune Disease Treatment May Not Dampen Immune System
4. Economy Doesnt Dampen Colorados Giving Spirit According to Statewide Giving and Volunteering Study
5. Experimental Drug May Dampen Severe Asthma
6. Obesity May Dampen Response to Asthma Meds
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. To evade chemotherapy, some cancer cells mimic stem cells
10. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
11. PET scans can accurately detect a breast tumors response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Can Dampen Chemo Drug Effectiveness 
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... ... NuevaCare, a leading home care agency based in San Mateo, California, but ... to announce information upgrades to its blog in the form of WordPress tags. The ... as home care (generally) as well as senior care and home care agency issues. ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation last ... in Neurology Award (PLINA). The couple joins a prestigious list of past PLINA ... Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. , ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: